NeRRe spins out KaNDy to develop NT-814

NeRRe Therapeutics Ltd. (Stevenage, U.K.) spun out KaNDy Therapeutics Ltd. (Stevenage, U.K.) to develop NT-814. The candidate has completed Phase IIa testing to treat postmenopausal vasomotor symptoms. NT-814 is a neurokinin 1 receptor (NK1R; TACR1) and NK3R antagonist.

NeRRe, which raised £23 million ($28.4 million) in a series B round earlier this year, spun out from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2012 (see BioCentury, Jan. 6). ...